Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular Vesicles as Emerging Regulators in Ischemic and Hypertrophic Cardiovascular Diseases: A Review of Pathogenesis and Therapeutics

Chen M., Wu Y., Chen C.

Narrative Review on Cardiovascular Disease, published in Med Sci Monit (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Med Sci Monit (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41088727
PMCID
PMC12539325
DOI
10.12659/msm.948948
Citations
2

Abstract (original English)

Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, have emerged as important regulators in specific cardiovascular conditions such as myocardial infarction, atherosclerosis, coronary artery disease, and cardiac hypertrophy. EVs mediate intercellular communication by transferring bioactive cargo such as proteins, lipids, and nucleic acids. EVs influence crucial pathological processes, including inflammation, fibrosis, apoptosis, and cardiac remodeling, contributing to disease progression. This review assessed the therapeutic potential of stem cell-derived EVs in reducing inflammation, enhancing angiogenesis, modulating immune responses, and mitigating cardiac remodeling. Specific EV-derived miRNAs such as miR-146a, miR-181b, and miR-21 exhibited beneficial effects in promoting cardiac repair, reducing fibrosis, and improving cardiac function after injury. Special focus is placed on stem cell-derived EVs, which show promise in reducing myocardial injury, promoting angiogenesis, and attenuating pathological hypertrophy. Moreover, we explore the emerging concept of EVs as biomarkers, with circulating endothelial- and platelet-derived EVs correlating with vascular dysfunction, plaque instability, and pro-coagulant activity in clinical studies. Despite their therapeutic promise, the clinical translation of EV-based strategies faces challenges, incl

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansCardiovascular DiseasesCardiomegalyMyocardial IschemiaMicroRNAsExosomesBiomarkersExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research